PBKR03
/ Passage Bio
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
January 18, 2024
GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
(clinicaltrials.gov)
- P1/2 | N=24 | Suspended | Sponsor: Passage Bio, Inc. | Active, not recruiting ➔ Suspended
Trial suspension • Pediatrics
January 05, 2023
GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
(clinicaltrials.gov)
- P1/2 | N=24 | Active, not recruiting | Sponsor: Passage Bio, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Pediatrics • NEFL
January 25, 2022
GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
(clinicaltrials.gov)
- P1/2; N=24; Recruiting; Sponsor: Passage Bio, Inc.; Initiation date: Sep 2021 ➔ Feb 2022
Trial initiation date • Pediatrics • MRI
September 17, 2021
GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
(clinicaltrials.gov)
- P1/2; N=24; Recruiting; Sponsor: Passage Bio, Inc.; Not yet recruiting ➔ Recruiting; Initiation date: Jun 2021 ➔ Sep 2021
Clinical • Enrollment open • Trial initiation date • Pediatrics • MRI
February 25, 2021
GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
(clinicaltrials.gov)
- P1/2; N=24; Not yet recruiting; Sponsor: Passage Bio, Inc.
Clinical • New P1/2 trial • Pediatrics • MRI
March 21, 2021
Study to assess safety, tolerability and efficacy of PBKR03 in pediatric subjects with Krabbe disease (GALax-C)
(clinicaltrialsregister.eu)
- P1/2; N=28; Sponsor: Passage Bio, Inc.
Clinical • New P1/2 trial • Lysosomal Storage Diseases • Metabolic Disorders • Pediatrics • Rare Diseases • MRI • Plasma NfL
1 to 6
Of
6
Go to page
1